# Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to-Moderate Alzheimer's Disease

> **NCT05578443** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University Union Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** 10g Astragalus
- **BEHAVIORAL:** Routine treatment
- **DRUG:** 20g Astragalus

## Key facts

- **NCT ID:** NCT05578443
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578443, "Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05578443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*